Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Are Emerging Markets Part Of Big Pharma's Core Business?

This article was originally published in PharmAsia News

Executive Summary

As Big Pharma companies increasingly look to emerging markets to capture some of the growth lost from the patent cliff in the U.S. and Europe, they are also shifting focus more to branded generics, leaving some investors to question whether companies would be better off spinning out their emerging market units, which would leave behind smaller companies focused on the core business of developing and marketing innovative therapies

You may also be interested in...



Emerging Markets Earnings Roundup: Pfizer (Part 4)

Pfizer considers the structure of its pharma operations in emerging markets as the dust begins to settle from its spin-off of its animal health business and the sale of its nutrition business.

Pfizer Sees Deeper Price Cuts, Lilly Maintains China Momentum – Emerging Market Earnings Roundup (Part 2)

Pfizer said that it has plans to rebound from a volatile fourth quarter of price cuts and slower than expected volume gains in emerging markets. Eli Lilly hopes to build on gains in China and boost volume growth overall in emerging markets to shore up revenues after major patents expired in key countries.

PharmAsia News Favorite Stories From 2011

If you missed some of the highlights of 2011, here’s your opportunity to check out some of our favorite stories from the year, as chosen by the editors of PharmAsia News.

Related Content

UsernamePublicRestriction

Register

SC078419

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel